Multiplexed MRM-based protein quantification of putative prognostic biomarkers for chronic kidney disease progression in plasma
Authors:
Open Access
- 16 March 2020
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 10 (1) , 1-12
Abstract
Current diagnostic measures for Chronic Kidney Disease (CKD) include detection of reduced estimated glomerular filtration rate (eGFR) and albuminuria, which have suboptimal accuracies in predicting disease progression. The disease complexity and heterogeneity underscore the need for multiplex quantification of different markers. The goal of this study was to determine the association of six previously reported CKD-associated plasma proteins [B2M (Beta-2-microglobulin), SERPINF1 (Pigment epithelium-derived factor), AMBP (Protein AMBP), LYZ (Lysozyme C), HBB (Hemoglobin subunit beta) and IGHA1 (Immunoglobulin heavy constant alpha 1)], as measured in a multiplex format, with kidney function, and outcome. Antibody-free, multiple reaction monitoring mass spectrometry (MRM) assays were developed, characterized for their analytical performance, and used for the analysis of 72 plasma samples from a patient cohort with longitudinal follow-up. The MRM significantly correlated (Rho = 0.5–0.9) with results from respective ELISA. Five proteins [AMBP, B2M, LYZ, HBB and SERPINF1] were significantly associated with eGFR, with the three former also associated with unfavorable outcome. The combination of these markers provided stronger associations with outcome (p < 0.0001) compared to individual markers. Collectively, our study describes a multiplex assay for absolute quantification and verification analysis of previously described putative CKD prognostic markers, laying the groundwork for further use in prospective validation studies.Keywords
Funding Information
- General Secretariat for Research and Innovation (Τ1ΕDΚ-03551, Τ1ΕDΚ-03551, T1EDK-03551)
- EU COST action CliniMARK
This publication has 87 references indexed in Scilit:
- Evolving importance of kidney disease: from subspecialty to global health burdenThe Lancet, 2013
- CKD273, a New Proteomics Classifier Assessing CKD and Its PrognosisPLOS ONE, 2013
- Plasma beta-2 microglobulin is associated with cardiovascular disease in uremic patientsKidney International, 2012
- Neutrophil Gelatinase-Associated Lipocalin (NGAL) and Kidney Injury Molecule 1 (KIM-1) as Predictors of Incident CKD Stage 3: The Atherosclerosis Risk in Communities (ARIC) StudyAmerican Journal of Kidney Diseases, 2012
- Chronic kidney disease-related atherosclerosis - proteomic studies of blood plasmaProteome Science, 2011
- Simultaneous Quantification of Apolipoprotein A-I and Apolipoprotein B by Liquid-Chromatography–Multiple- Reaction–Monitoring Mass SpectrometryClinical Chemistry, 2010
- Naturally Occurring Human Urinary Peptides for Use in Diagnosis of Chronic Kidney DiseaseMolecular & Cellular Proteomics, 2010
- Identification and Assessment of Plasma Lysozyme as a Putative Biomarker of AtherosclerosisArteriosclerosis, Thrombosis, and Vascular Biology, 2010
- Skyline: an open source document editor for creating and analyzing targeted proteomics experimentsBioinformatics, 2010
- Review on uremic toxins: Classification, concentration, and interindividual variabilityKidney International, 2003